Androgen-deprivation therapy (ADT) can be associated with significant psychological effects in patients with prostate cancer. Additionally, these side effects—which include depression, Alzheimer disease, and coronary disease—are often under-reported by patients. Read the article here.
Psychological Effects From ADT a Growing Challenge in Prostate Cancer Read More »
Reducing testosterone levels with androgen deprivation therapy, or A.D.T., is a common treatment for prostate cancer. But a new study has found that it more than doubles the risk of dementia. Read the article here.
Prostate Cancer Treatment Can Raise Dementia Risk Read More »
When elderly men with localized prostate cancer are given androgen-deprivation therapy (ADT), the risk of depression and hospitalization for psychiatric treatment is significantly increased, a population-based study of 78,000 U.S. men showed. Read the article.
ADT May Increase Depression Risk in Prostate Cancer Read More »
The results of a study support an association between the use of androgen deprivation therapy (ADT) in the treatment of prostate cancer and an increased risk of Alzheimer’s disease in a general population cohort. Read the article.
Common prostate cancer treatment may double Alzheimer’s risk Read More »
January 2016 Awareness Night Understanding, preventing and managing side effects of hormone therapy. Dr. Shabbir Alibhai,MSc, MD, FRCPC,Princess Margaret Cancer Centre Senior Scientist, Toronto General Research Institute (TGRI) Scientist, Toronto Rehabilitation Institute (TRI) Asst Prof, Depts of Medicine and Health Policy, Management, and Evaluation at the U of Toronto CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 43:32 minutes
Prostate cancer survivors are most likely to die from something other than cancer, with cardiovascular disease as the most common cause, according to a new study. Androgen deprivation therapy, or ADT, may increase several cardiovascular risk factors that contribute to heart disease and adverse cardiovascular events, researchers at Vanderbilt University report. Read the article.
Prostate cancer survivors more likely to die of other diseases Read More »
July 2015 Scotiabank Awareness Night Radiation and Hormone Therapy Dr. Gerard Morton, MB BCh BAO, MRCPI, FRCPC, FFRRCSI Associate Professor , Department of Radiation Oncology, University of Toronto Radiation Oncologist, Sunnybrook Odette Cancer Centre Head of Brachytherapy, Sunnybrook Odette Cancer Centre Chair, Ontario Association of Radiation Oncologists Affiliate scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 43:11 minutes
Video: Dr. Gerard Morton, “Radiation and Hormone Therapy” Read More »
Continuation of androgen deprivation therapy for an additional 24 months improves all disease end points during 15 years of follow-up compared with short-term androgen deprivation in men with locally advanced prostate cancer treated with radiotherapy. Read the article.
Long-term ADT Best for Locally Advanced Prostate Cancer Read More »
The addition of hormonal therapy to salvage radiotherapy demonstrated a significant survival benefit in patients with prostate cancer recurrence after radical prostatectomy, according to long-term follow-up data from a randomized trial. Read the article.
Combining Radiotherapy With Anti-Androgen Improves Prostate Cancer Survival Read More »
Men with prostate cancer who also have had a heart attack may fare better with radiation therapy alone rather than with the standard treatment of radiation plus hormone therapy, a new analysis suggests. Over an average of 17 years of follow-up, men with high-risk prostate cancer who also had a heart condition lived longer after radiation treatment alone than similar men who had radiation and hormone therapy. Men who didn’t have heart problems lived longer if they had both treatments, the researchers added. Read the article.
Some Prostate Cancer Patients May Not Benefit From Hormone Therapy Read More »